Sarin S K, Sachdev G, Nanda R
Ann Surg. 1986 Jul;204(1):78-82. doi: 10.1097/00000658-198607000-00011.
One hundred one patients, 54 with cirrhosis of liver, 31 with noncirrhotic portal fibrosis (NCPF), and 16 with extrahepatic obstruction (EHO), were followed up at monthly intervals for a mean (+/- SD) period of 17.9 +/- 4.8 months after achieving total variceal eradication with endoscopic sclerotherapy. Recurrence of esophageal varices was seen in 19 (18.8%) patients, 12 with cirrhosis and seven with NCPF, within a mean (+/- SD) period of 5.7 +/- 1.6 months. No patient with EHO showed recurrence. Three (2.9%) patients rebled from the recurred varices. Mean (+/- SD) number of sclerotherapy sessions and the amount of absolute alcohol required for eradication of recurred varices were 1.6 +/- 0.8 and 3.6 +/- 1.8 ml, respectively. Dysphagia and esophageal stricture were present in 15 (14.9%) patients with nearly similar frequency in patients with cirrhosis, NCPF, and EHO. Dysphagia in four patients with stricture improved without dilatation. While there were no deaths in patients with NCPF and EHO, 11 patients with cirrhosis died. There was significant (p less than 0.01) improvement in the liver status of surviving patients with cirrhosis after variceal eradication. It can be concluded that variceal recurrence and rebleeding are not major problems after sclerotherapy. Sclerotherapy probably helps in spontaneous improvement of the liver status of surviving cirrhotics and reduces long-term morbidity and mortality of patients with NCPF and EHO.
101例患者,其中54例为肝硬化患者,31例为非肝硬化性门脉纤维化(NCPF)患者,16例为肝外梗阻(EHO)患者,在内镜下硬化治疗实现静脉曲张完全根除后,每月进行随访,平均(±标准差)随访期为17.9±4.8个月。19例(18.8%)患者出现食管静脉曲张复发,其中12例为肝硬化患者,7例为NCPF患者,平均(±标准差)复发时间为5.7±1.6个月。EHO患者无复发。3例(2.9%)患者因复发的静脉曲张再次出血。根除复发静脉曲张所需的硬化治疗平均(±标准差)次数和无水乙醇用量分别为1.6±0.8次和3.6±1.8 ml。15例(14.9%)患者出现吞咽困难和食管狭窄,在肝硬化、NCPF和EHO患者中的发生率相近。4例有狭窄的吞咽困难患者未经扩张治疗病情改善。NCPF和EHO患者无死亡病例,11例肝硬化患者死亡。静脉曲张根除后,存活的肝硬化患者肝脏状况有显著(p<0.01)改善。可以得出结论,硬化治疗后静脉曲张复发和再出血不是主要问题。硬化治疗可能有助于存活的肝硬化患者肝脏状况的自发改善,并降低NCPF和EHO患者的长期发病率和死亡率。